AstraZeneca and Karolinska Institutet enter pharma deals to establish a unique integrated cardiovascular and metabolic research centre as part of a $100 million joint venture.

As part of the pharma deals, AstraZeneca, a big pharma company will be contributing up to $100 million over an initial 5 years.

For the first time AstraZeneca and KI scientists will work together under one director in the pharma deals.

The ”Karolinska Institutet/AstraZeneca Integrated Cardio Metabolic Centre” is AstraZeneca’s largest ever pharma deals collaboration with a Swedish academic institution.

It is also the first time that scientists from Karolinska Institutet will work side by side with scientists from a pharmaceutical company under the leadership of one director, as part of the pharma deals.

Related

Report: Cardiovascular Partnering Terms and Agreements

Report: Metabolic Partnering Terms and Agreements

Report: Partnering Deals and Alliances with AstraZeneca

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter